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Abstract
In 1971, the “War on Cancer” was launched by the US government to cure cancer by the 200-year anniversary of the
founding of the United States of America, 1976. This article briefly looks back at the progress that has been made in
cancer research and compares progress made in other areas of human affliction. While progress has indeed been
made, the battle continues to rage on.
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The Federal government of the United States has launched many initia-
tives. In fact, this year marks the 40-year anniversary of the Apollo 11
mission that landed the first humans (Armstrong and Aldrin) on the
moon on July 20, 1969. This event fulfilled the goal laid out by Presi-
dent John F. Kennedy of reaching the moon where he stated in a joint
session of congress on May 25, 1961: “I believe that this nation should
commit itself to achieving the goal, before this decade is out, of landing
a man on the moon and returning him safely to the Earth.” This event
was viewed by millions of people including President Richard Nixon
who watched the proceedings from theOval Office of theWhite House
when Neil Armstrong stepped off the Eagle onto the moon and uttered
those now infamous words “That’s one small step for man, one giant
leap for mankind.” In 1971, flush with the nation’s success in landing
a man on the moon, President Nixon launched a new national goal,
that is, to cure cancer by the nations’ bicentennial year of 1976. The
National Cancer Act of 1971 was signed into law on December 23,
1971, and became known as the “War on Cancer.” The goal was to
eradicate cancer as a major cause of death in the United States. A
renewed focus was introduced by Dr. Andrew von Eschenbach, the
director of the National Cancer Institute in the form of a Director’s
Challenge in 2003 “to eliminate the suffering and death from cancer”
and to do so by 2015. Recently, the US Senate passed a new bill
(S. 717) called the “21st Century Cancer Access to Life-Saving Early
Detection, Research and Treatment (ALERT) Act” with the aims to
increase funding and patient access to clinical trials and information.
Toward that end, President Obama published a plan to combat cancer
by doubling funding within a 5-year period as part of a drive to find
“a cure for cancer in our time.” On September 30, 2009, Obama an-
nounced a $1 billion spending plan earmarked for research into the
genetic causes of cancer and targeted treatments.
Overall, progress in the reduction of the overall cancer mortality rate
has not been what had been envisioned when the War of Cancer was
launched in 1971. However, experts point to age-specific mortality
rates that have steadily improved for several decades to show that prog-
ress has been made. The National Cancer Institute has spent a little
more than $100 billion since the war on cancer began averaging about
$2.7 billion annually (without inflation adjustments) during a 37-year
period. By comparison, smallpox was targeted in the 1960s. Ten years
and $300 million dollars later, one of history’s greatest killer of humans
was eradicated. Based on the smallpox success, public health experts
were inspired to target other diseases such as polio. During a 21-year
period, approximately $18 billion was spent or $240 million per year
(less than the cost for the United States to occupy Iraq per day to place
that number in perspective). An estimated 4 million children have
been saved from paralysis by the inoculation campaigns. If we compare
the progress in the war on cancer with other national priorities, such
as reducing the death rate from heart disease. Which has decreased
by 64% in the same time span, we are in fact not doing very well.
This has raised questions and doubt in the media regarding the wis-
dom of continuing to support the War on Cancer when in fact con-
tinued funding for cancer research is vital and progress is being made
on many fronts. Each publication in Neoplasia represents one small
step in the War on Cancer toward that final giant leap.
Address all correspondence to: Alnawaz Rehemtulla, PhD, University of Michigan, 109
Zina Pitcher Pl, Biomedical Sciences Research Bldg, Ann Arbor, MI 48109-2200.
E-mail: alnawaz@umich.edu
Received 3 November 2009; Revised 3 November 2009; Accepted 3 November 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.91866
www.neoplasia.com
Volume 11 Number 12 December 2009 pp. 1252–1263 1252
Truth be told, progress in cancer research is hard for many reasons.
Upon reflection, progress in cellular and molecular biology tools used
every day by investigators to interrogate tumor cells and their complex
interconnecting genetic and signaling pathways have not been around
all that long and are rapidly improving and expanding in their capa-
bilities. This has lead to the apparent paradox that the more we study
cancer, the more complex it appears. It is also interesting to note that
like in all science disciplines, cancer research can also be distracted by
fads and political agendas that come and go over time. Competing
agendas and biases in funding decisions seem to almost be on par with
disagreements and spirited discussions involving tumor cell lines, geneti-
cally engineered models versus xenograft models, target identification/
selection, and so on. Despite the seemingly inefficient research process,
the war on cancer rages on and progress is being made on multiple
fronts. My expectation that at some point in the future, the different
present skirmishes and small battles that we have and are winning will
add together to provide for a much clearer pathway or exit strategy for
this war where we will in fact be victorious.
As the Editor of Neoplasia, it is my job to work closely with the
Editorial Board members to oversee the scientific content of the jour-
nal. Dissemination of valuable articles that can assist other investigators
in the war on cancer in a timely fashion is vital for all investigators.
During the past 3 years (2007-2009), Neoplasia has published many
articles ranging in areas of research involving genetics, biology, ani-
mal models to clinical investigations (Table 1). Articles published in
Neoplasia continue to be of excellent quality and content. Neoplasia
continues to provide its readership with a broad coverage of the many
exciting discoveries. One of the central goals of Neoplasia is rapid dis-
semination of information. As such, Neoplasia will continue to provide
immediate open access to all of its published articles at the time of
publication through PubMed Central. This approach allows Neoplasia
articles to be accessible immediately to the worldwide cancer research
and clinical community. This feature also provides authors’ research
findings available to the largest possible readership ensuring that arti-
cles published in Neoplasia will have significant impact.
In summary, Neoplasia will continue to provide high-quality content
in an effort to provide investigators with the information necessary to
most efficiently fight the war on cancer. It is my pleasure along with
our Editorial Board to continue to serve the scientific community in
this fashion.
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